HIGHLIGHTS
SUMMARY
Overexpression of MYCN or the constitutively active mutant of ALK, e_g, ALKF1174L, in neural crest cells can induce neuroblastoma in mice. Drug resistance against ALK inhibitors and the absence of direct antagonists for MYCN limit the treatment of neuroblastoma in clinic. Unlike most PI3K signaling-driven tumors, mutations in PIK3CA and PTEN are infrequent in neuroblastoma, suggesting the distinct oncogenic mechanism of the PI3K signaling in the carcinogenesis of the neuroblastoma. The authors found that inhibition of p110α induced ALK instability and synergized the inhibitory effects of ALK inhibitors on neuroblastoma cells. Considering the . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.